Watchlist Price Alert

Ocuphire Pharma Inc. (OCUP)

NASDAQ: OCUP · Real-Time Price · USD

1.17

-0.16 (-12.03%)

At close: Oct 23, 2024, 10:00 PM

-12.03% (1D)

Bid	n/a
Market Cap	31.74M
Revenue (ttm)	465K
Net Income (ttm)	-61.35M
EPS (ttm)	-0.54
PE Ratio (ttm)	-2.1666666666666665
Forward PE	n/a
Analyst	Buy

Ask	n/a
Volume	675,971
Avg. Volume (20D)	139,151
Open	1.33
Previous Close	1.33
Day's Range	1.07 - 1.36
52-Week Range	1.07 - 3.40
Beta	0.31

About OCUP

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OCUP

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OCUP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

8 months ago

+0%

Ocuphire Pharma shares are trading higher after th... Unlock content with Pro Subscription

10 months ago

-21.08%

Ocuphire Pharma shares are trading lower after the company reported worse-than-expected Q2 financial results.

News

8 months ago · benzinga.com

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal

On Wednesday, Ocuphire Pharma, Inc. OCUP announced the all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases (IRDs).

8 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics. Click here to ...

10 months ago · zacks.com

Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates

Ocuphire Pharma, Inc. (OCUP) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.